Recurrent miscarriage is defined as the loss of three or more consecutive pregnancies.
Endocrine
Women with polycystic ovary syndrome are at higher risk of miscarriage, which may be related to insulin resistance and hyperinsulinaemia. There is insufficient evidence to support the use of metformin during pregnancy to reduce this risk. Uncontrolled diabetes mellitus is a risk factor for recurrent miscarriage.
Immune
Women with recurrent miscarriage have more natural killer cells in their uterine mucosa than controls and those with the highest levels have a correspondingly high rate of miscarriage in subsequent pregnancies. However, there is no association between the levels of natural killer cells in peripheral blood and the levels in the uterine mucosa. Levels of natural killer cells in peripheral blood are not predictive of pregnancy outcome in women with unexplained recurrent miscarriage.
Inherited thrombophilia
Inherited thrombophilia, such as protein C and protein S deficiency, may have a role in recurrent miscarriage, because of an increased risk of thrombosis in the uteroplacental circulation, although the evidence for a causal effect is weak [5] . The relationship appears to be strongest for late pregnancy loss as opposed to miscarriage. Women with second-trimester miscarriage should be screened for inherited thrombophilia.
Infections
Bacterial vaginosis in the first trimester is a risk factor for second-trimester miscarriage and preterm delivery [6] .
Investigations
Antiphospholipid and B2-glycoprotein I antibodies:
The presence of these is associated with early miscarriages and maternal morbidity and is referred to as primary APS. There is requirement for two tests at least six weeks apart showing either lupus anticoagulant or anticardiolipin antibodies at significant levels. Women with recurrent first-trimester miscarriage and all women with one or more second-trimester miscarriages should be screened for antiphospholipid antibodies before pregnancy.
Women with second-trimester miscarriage should be screened for inherited thrombophilias including factor V Leiden, factor II (prothrombin) gene mutation and protein S. All women with recurrent first-trimester miscarriage and all women with one or more second-trimester miscarriages should have pelvic ultrasound to assess uterine anatomy.
Women who have had one or more second-trimester miscarriages and suspected cervical weakness may be offered serial cervical sonographic surveillance. If uterine anomalies are detected then further investigations, such as hysteroscopy and/or laparoscopy, may be required.
Karyotyping
Karyotyping of products of conception should be undertaken on the products of conception from the third (and any subsequent) miscarriages. If an unbalanced structural chromosomal abnormality is found, referral to genetics is indicated [1] .
Parental peripheral blood karyotyping of both partners should be performed in couples with recurrent miscarriage where testing of products of conception reports an unbalanced structural chromosomal abnormality.
NB: the Royal College of Obstetricians and Gynaecologists (RCOG) does not recommend routine screening for diabetes, inherited coagulopathies, thyroid disease, serum prolactin, or TORCH syndrome (toxoplasmosis, other, rubella, cytomegalovirus, herpes simplex) [1] .
Management
General advice [4] Reassurance should be given about the high probability of a successful outcome. In a large trial that included women with 4.2 consecutive miscarriages and an average age of 32.7 years, the placebo group was shown to have a live birth rate of 65%. There is a suggestion that the reassurance gained from frequent antenatal visits and ultrasound examinations may improve outcomes.
Pharmacological treatment Heparin
In primary APS patients, heparin combined with low-dose aspirin improves live birth rate to 70% from reported rates in untreated women with APS of as low as 10% [7] . A systematic review and meta-analysis has shown no reduction in the risk of miscarriage in women with inherited thrombophilia treated with low molecular weight heparin (LMWH) [5] .
There is some evidence suggesting that use of metformin during pregnancy is associated with a reduction in the miscarriage rate in women with polycystic ovary syndrome [8] . However, the data are contradictory and a systematic review and metaanalysis found no effect on the miscarriage risk [9] .
The RCOG does not recommend its use in pregnancy at present, until further randomised prospective study results are available to provide adequate evidence of safety and efficacy of its use.
Progesterone
The progesterone in recurrent miscarriage (PROMISE) study, a large randomised, double-blind, placebo-controlled multicentre trial, has shown [10] :
No benefit from progesterone supplementation in women with unexplained recurrent miscarriages.
No sign that progesterone delays the time of miscarriage. Over 60% of the women who conceived within a year of inclusion in the study, all of whom had a history of recurrent miscarriage, had a live birth, whether they had progesterone treatment or placebo.
Human chorionic gonadotrophin (hCG) hormone
The evidence supporting hCG supplementation to prevent recurrent miscarriage is equivocal; higher-quality evidence shows no benefit [11] .
Immunotherapy
Paternal cell immunisation, third-party donor leukocytes, trophoblast membranes, and intravenous immunoglobulin have all been used to treat women with otherwise unexplained miscarriage. None has shown any significant benefit over placebo in improving the live birth rate [12] .
Surgical treatment [13] Cervical cerclage (a Shirodkar or McDonald suture) is a prophylactic measure inserted around 12-14 weeks, when cervical incompetence is suspected. However, cervical incompetence may be overdiagnosed as a cause of second-trimester miscarriage. The cerclage procedure also carries a risk of stimulating uterine contractions.
In women with a history of one second-trimester miscarriage attributable to cervical factors and a singleton pregnancy, a cerclage should be offered if a cervical length of ≤25 mm is detected by transvaginal scan before 24 weeks of gestation [1] . In the USA, 1 in 300 women receive a cerclage but the rate is over 1% in many other populations. Preconceptual abdominal cerclage is increasingly used; there is no evidence that it has any detrimental effects but evidence of benefit is still lacking.
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